Experienced in Neurosyphilis

Dr. Raymond S. Turner

Neurology
Medstar Medical Group Ii LLC
3800 Reservoir Rd Nw, 
Washington, DC 
Experienced in Neurosyphilis
Medstar Medical Group Ii LLC
3800 Reservoir Rd Nw, 
Washington, DC 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Raymond Turner is a Neurologist in Washington, Washington, D.c.. Dr. Turner is rated as an Experienced provider by MediFind in the treatment of Neurosyphilis. His top areas of expertise are Alzheimer's Disease, Dementia, Developmental Dysphasia Familial, and Memory Loss.

His clinical research consists of co-authoring 75 peer reviewed articles and participating in 13 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Neurosyphilis.

Specialties
Neurology
Licenses
Psychiatry & Neurology in MI
Hospital Affiliations
Medstar Georgetown University Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D

Locations

MEDSTAR MEDICAL GROUP II LLC
3800 Reservoir Rd Nw, Washington, DC 20007

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

12 Clinical Trials

Long-Term Nicotine Treatment of Mild Cognitive Impairment
Long-Term Nicotine Treatment of Mild Cognitive Impairment
Enrollment Status: Completed
Publish Date: October 01, 2025
Intervention Type: Drug
Study Drug: Nicotine Transdermal Patch
Study Phase: Phase 2
Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimer's Disease
Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimer's Disease
Enrollment Status: Active_not_recruiting
Publish Date: August 29, 2025
Intervention Type: Drug
Study Drug: Donanemab
Study Phase: Phase 3
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Study Evaluating the Safety and Efficacy of Simufilam 100 mg Tablets in Subjects With Mild-to-Moderate Alzheimer's Disease
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Study Evaluating the Safety and Efficacy of Simufilam 100 mg Tablets in Subjects With Mild-to-Moderate Alzheimer's Disease
Enrollment Status: Completed
Publish Date: May 25, 2025
Intervention Type: Drug
Study Drug: Simufilam
Study Phase: Phase 3
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Efficacy, Safety and Biomarker Effects of ALZ-801 in Subjects With Early Alzheimer's Disease and APOE4/4 Genotype
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Efficacy, Safety and Biomarker Effects of ALZ-801 in Subjects With Early Alzheimer's Disease and APOE4/4 Genotype
Enrollment Status: Completed
Publish Date: May 16, 2025
Intervention Type: Drug
Study Drug: ALZ-801
Study Phase: Phase 3
Metformin in Alzheimer's Dementia Prevention
Metformin in Alzheimer's Dementia Prevention
Enrollment Status: Active_not_recruiting
Publish Date: February 19, 2025
Intervention Type: Drug
Study Drug: Metformin
Study Phase: Phase 2/Phase 3
Therapeutic Effects of Intranasally-Administered Insulin in Adults With Amnestic Mild Cognitive Impairment (aMCI) or Mild Alzheimer's Disease (AD)
Therapeutic Effects of Intranasally-Administered Insulin in Adults With Amnestic Mild Cognitive Impairment (aMCI) or Mild Alzheimer's Disease (AD)
Enrollment Status: Completed
Publish Date: November 20, 2024
Intervention Type: Drug
Study Phase: Phase 2/Phase 3
Trial Ready Cohort for the Prevention of Alzheimer's Dementia (TRC-PAD)
Trial Ready Cohort for the Prevention of Alzheimer's Dementia (TRC-PAD)
Enrollment Status: Completed
Publish Date: June 27, 2024
Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4 Study)
Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4 Study)
Enrollment Status: Completed
Publish Date: December 28, 2023
Intervention Type: Drug
Study Drug: Solanezumab
Study Phase: Phase 3
GAIN Trial: A Randomized, Double-Blind, Placebo-Controlled Study of COR388 in Subjects With Alzheimer's Disease
GAIN Trial: A Randomized, Double-Blind, Placebo-Controlled Study of COR388 in Subjects With Alzheimer's Disease
Enrollment Status: Completed
Publish Date: February 23, 2023
Intervention Type: Drug
Study Drug: COR388
Study Phase: Phase 2/Phase 3
A Phase 2a Combined Open-Label and Double-Blind, Placebo-Controlled Crossover Study Assessing the Effectiveness, Safety, and Tolerability of Oral Fasudil in Subjects With Dementia and Wandering Behaviors of Elopement and/or Getting Lost
A Phase 2a Combined Open-Label and Double-Blind, Placebo-Controlled Crossover Study Assessing the Effectiveness, Safety, and Tolerability of Oral Fasudil in Subjects With Dementia and Wandering Behaviors of Elopement and/or Getting Lost
Enrollment Status: Completed
Publish Date: July 11, 2022
Intervention Type: Drug
Study Drug: Oral Fasudil
Study Phase: Phase 2
A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Aducanumab (BIIB037) in Subjects With Early Alzheimer's Disease
A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Aducanumab (BIIB037) in Subjects With Early Alzheimer's Disease
Enrollment Status: Terminated
Publish Date: September 02, 2021
Intervention Type: Drug
Study Phase: Phase 3
A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)
A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)
Enrollment Status: Terminated
Publish Date: December 03, 2019
Intervention Type: Drug
Study Phase: Phase 2/Phase 3
View 11 Less Clinical Trials

75 Total Publications

Speech production as an artificial intelligence-based 'process' measure of cognition sensitive to mild cognitive impairment and Alzheimer's disease.
Speech production as an artificial intelligence-based 'process' measure of cognition sensitive to mild cognitive impairment and Alzheimer's disease.
Journal: The Clinical neuropsychologist
Published: July 07, 2025
Similar Doctors
Experienced in Neurosyphilis
Dr. Crystal S. Janani
Neurology
Experienced in Neurosyphilis
Dr. Crystal S. Janani
Neurology

St Agnes Healthcare Inc

3407 Wilkens Ave, 
Baltimore, MD 
 (33.0 miles away)
Languages Spoken:
English, Farsi
See accepted insurances
Accepting New Patients
Offers Telehealth

Crystal Janani is a Neurologist in Baltimore, Maryland. Dr. Janani is rated as an Advanced provider by MediFind in the treatment of Neurosyphilis. Her top areas of expertise are Seizures, Generalized Tonic-Clonic Seizure, Neurosyphilis, and Memory Loss. Dr. Janani is currently accepting new patients.

Experienced in Neurosyphilis
Dr. Francois Boller
Neurology
Experienced in Neurosyphilis
Dr. Francois Boller
Neurology
4301 Military Rd Nw, 
Washington, DC 
 (3.9 miles away)
202-352-7274
Languages Spoken:
English

Francois Boller is a Neurologist in Washington, Washington, D.c.. Dr. Boller is rated as an Experienced provider by MediFind in the treatment of Neurosyphilis. His top areas of expertise are Charles Bonnet Syndrome, Phantom Limb Pain, Neurosyphilis, and Complex Regional Pain Syndrome.

Experienced in Neurosyphilis
Dr. Mark M. Lin
Neurology
Experienced in Neurosyphilis
Dr. Mark M. Lin
Neurology

Mgmc LLC

106 Irving St Nw, Mgmc Llc At Whc Pob, 
Washington, DC 
 (3.5 miles away)
202-877-3000
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Mark Lin is a Neurologist in Washington, Washington, D.c.. Dr. Lin is rated as an Advanced provider by MediFind in the treatment of Neurosyphilis. His top areas of expertise are Epilepsy, Memory Loss, Seizures, and Headache. Dr. Lin is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Turner's expertise for a condition
ConditionClose
    View All 8 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile